Cryptome completes acquisition of HealthLinx

21-Feb-2006

Cryptome Pharmaceuticals Limited announced that it has completed the acquisition of HealthLinx Pty Ltd. HealthLinx, a privately held company before its acquisition, focuses on biomarkers and the development of diagnostics, with its lead candidates targeting ovarian cancer and complications in pregnancy. This follows the approval by shareholders of the transaction at the extraordinary general meeting.

The all-scrip acquisition has been accompanied by a capital raising of $2 million, which provides a strong funding base for the business, alongside revenue to be generated by the previously announced Dairy Australia contract. The merged entity will be known as HealthLinx Limited (HealthLinx). A new ASX code will be allocated and advised shortly.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures
View topic world
Topic world Diagnostics

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures